Franquiz Miguel J, Short Nicholas J
Baylor College of Medicine, Houston, TX, USA.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Biologics. 2020 Feb 14;14:23-34. doi: 10.2147/BTT.S202746. eCollection 2020.
Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.
在过去十年中，B细胞急性淋巴细胞白血病（ALL）的治疗取得了多项进展，这主要得益于对该疾病免疫病理生物学的深入了解。双特异性抗体blinatumomab可协调细胞毒性CD3+ T淋巴细胞和CD19+淋巴母细胞，其临床应用已使复发/难治性及微小残留病阳性的B细胞ALL患者的预后得到改善。有前景的新数据也证明了该药物在一线治疗及联合方案中的疗效。关于blinatumomab与细胞毒性化疗及其他新药的最佳序贯和联合方式仍存在不确定性。本文将综述blinatumomab用于成人B细胞ALL单药治疗及联合治疗的药理学和临床数据。
